DNA Sequencing Equipment and Services Markets, 3rd. Edition


Published on

1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

DNA Sequencing Equipment and Services Markets, 3rd. Edition

  1. 1. DNA Sequencing Equipment and Services Markets, 3rd. EditionReport Details:Published:September 2012No. of Pages: 180Price: Single User License – US$3995This report, DNA Sequencing Equipment and Services Markets, represents the third timeKalorama has detailed the market for DNA sequencing systems, as well as consumables used insequencing and sequencing services. Much has changed since the last Kalorama edition of thisreport. More companies are offering sequencing services. The market was moving in a relativelylinear manner for about two years in terms of competition, with no disruptive technologies orbusiness models introduced. After a period of relative stability, the market has seen majordevelopments in 2011 and 2012. The introductions of the Ion Torrent PGM, PacBio RS and MiSeqhave changed the situation in the market, with more new technologies expected from Ion Torrentas well as Oxford Nanopore.DNA sequencing can be defined as any biochemical method for determining the order of thenucleotide bases, adenine, guanine, cytosine, and thymine, (A,G,C,T) in a DNA nucleotide. DNASequencing has accelerated research and discovery, which created a brisk market for sequencingsystems that perform this work. The growing availability of vast amounts of annotated sequencedata permits life science researchers to undertake a much wider range of experiments.As part ofthe report’s coverage, the following data is provided:•Current Market Estimate•Historical Market Data since 2006•Forecast to 2016•Review of Major Company Sequencing Products•The Status of Next Gen Systems•Clinical Applications vs. Research Applications in Sequencing•Litigation and Intellectual Property Developments•Deals in the Industry•Market Share of Major Players•Challenges and Strategic RecommendationsIt is the beginning of a revolutionary time for the life sciences. Pricing changes, purchases by first-time users. Consortia, initiatives, a Groups have been organizing to sequence hundreds orthousands of individuals, species, tumors and the like in a short period of time – the 1,000Genomes Project, the 1,001 Arabidopsis Project, and many others, many of which are covered inthe Trends section of the report. Longer-term, questions still remain for broad areas that are seen
  2. 2. as large opportunities, such as disease prevention and diagnostics.The market remains volatile, but some patterns have been stabilizing in recent years. The reportuses primary and secondary research to present market watchers with an assessment of themarketplace in 2012. As part of its coverage, the report profiles the following companies:•454 Life Sciences (Roche)•Complete Genomics•Illumina•Life Technologies•Pacific BiosciencesAs the report details, the science is constantly evolving, and trends could work against DNAsequencers for some reason. Microarrays are still more cost-effective for GWAS, but given thetrends in the science and the sequencing costs, it seems inevitable that will change. Furthercomplicating things, somatic mutations, viral genome insertions, and epigenetic changes continuethroughout life. The competition has been brutal as systems are constantly improved and newproducts are appearing with increasing frequency. Longer-term, new segments in diagnostics andindustry are likely to open up further. The pharmaceutical industry is likely to be a growingsegment, due to personalized medicine and other genomics-related projects.Get your copy of this report @http://www.reportsnreports.com/reports/195656-dna-sequencing-equipment-and-services-markets-3rd-edition.htmlMajor points covered in Table of Contents of this report includeTable Of ContentsCHAPTER ONE: EXECUTIVE SUMMARYIntroductionNew Systems, Services Create UncertaintyA Period of Rapid Adoption, But Lower PricesFurther Longer-Term ChallengesRapid Growth Overall, But Intense CompetitionCustomers’ Research Models EvolvingEstablished Next-Generation Systems Seeing SlowdownBackgroundScope and MethodologyApplications and DefinitionsTypes of SamplesDNA Sequencing StrategiesCHAPTER TWO: SEQUENCER MARKET TRENDSIndustry and Technology TrendsMarket Fragmenting Into Multiple Product Types and ApplicationsContinual Improvements Expand Sequencer Market
  3. 3. Acquisitions and Collaborations for New TechnologiesPatent Infringement, Other Legal DisputesSlow Path to Potentially Large Clinical MarketsSpread of Targeted Enrichment, Sequence-Capture Products and ServicesSynergies Appearing Between Life Science Companies’ ProductsConsumer Genomics, Genetic Testing, Pharmacogenetics Still Entering MainstreamNHGRI Funding, Budget, Periodic Strategic PlanningNHGRI Shifts Funds from Centralized Sequencing CentersNHGRI White Paper #4: The Future of Genome SequencingGenome Projects and ConsortiaThe Cancer Genome Atlas (TCGA) ProjectNational Plant Genome InitiativeNSF/USDA Microbial Genome Sequencing ProgramCHAPTER THREE: DNA SEQUENCING SYSTEMS AND TECHNOLOGIES454 Life Sciences (Roche)Genome Sequencer FLX, FLX+, JuniorIlluminaHiSeq, HiScan SQ, MiSeq, Genome Analyzer IIxIntelligent Biosystems (Qiagen)/Azco BiotechLI-COR Biosciences 4300Life Technologies/Applied BiosystemsABI Prism 310 Genetic AnalyzerABI Prism 3100-Avant Genetic AnalyzerApplied Biosystems 3100 Genetic AnalyzerApplied Biosystems 3130 Genetic AnalyzerApplied Biosystems 3130xl Genetic AnalyzerApplied Biosystems 3500 Genetic AnalyzerApplied Biosystems 3730 DNA AnalyzerApplied Biosystems 3730xl DNA AnalyzerABI SOLiD 4, 5500, 5500xl, 5500xl W Genetic AnalyzersIon Torrent Personal Genome Machine (PGM)Pacific BiosciencesPacBio RSTechnologies Under DevelopmentIntroductionHuman Microbiome Project Technology Development AwardsCHAPTER FOUR: SEQUENCING MARKET ANALYSISRevenues ForecastHistorical RevenuesOverall Market Forecast
  4. 4. Sequencing For a Clinical PurposeRocheABIIlluminaAffymetrixB.C. Cancer AgencyEmory Genetics LabBacterial and Viral Applications for NGSeGenomicsBGIPacific BiosciencesClinical Sequencing vs. Research Sequencing MarketsCHAPTER FIVE: COMPETITIVE ANALYSISIntroductionBenchtop and Third-Generation Sequencers Bring InstabilitySecond-, Third-Generation Battle Still Undefined, UnresolvedIncreased Flexibility with PurchasingABI Capillary Electrophoresis Holds Onto Large SegmentDNA Sequencer Market SharesSmaller Companies Experiencing StrugglesFeatures and Strengths of Second-Generation Sequencers454 Life Sciences GS FLX–Strengths/Advantages454 Life Sciences GS FLX–Weaknesses/Disadvantages454 Life Sciences GS Junior–Strengths/Advantages454 Life Sciences GS Junior–Weaknesses/DisadvantagesApplied Biosystems SOLiD–Strength/AdvantagesApplied Biosystems SOLiD–Weaknesses/DisadvantagesIllumina HiSeq/HiScan SQ–Strength/AdvantagesIllumina HiSeq/HiScan SQ–Weaknesses/DisadvantagesIllumina MiSeq - Strength/AdvantagesIllumina MiSeq-Weaknesses/DisadvantagesLife Technologies PGM-Weaknesses/DisadvantagesPacific Biosciences PacBio RS-Strength/AdvantagesPacific Biosciences PacBio RS-Weaknesses/DisadvantagesCHAPTER SIX: INTELLECTUAL PROPERTY AND LITIGATIONDevelopmentsHelicos’ Patent Infringement Suit Against PacBio, Life Technologies, and IlluminaIntelligent Bio-Systems and Columbia University Sue Illumina for InfringementIllumina’s Two Lawsuits Against Complete Genomics for InfringementIllumina Sues Life Technologies Over Ion Torrent Systems
  5. 5. Class Action Shareholder Lawsuit Filed Against Pacific BiosciencesAffymetrix Dismisses Suit Against Pacific Biosciences and Former EmployeesLife Technologies Defeats VisiGen Stakeholders After ArbitrationCatalyst Assets Sues Life Technologies for InfringementPatent Interference Between Life Technologies and Pacific BiosciencesLife Technologies and Illumina Dispute Over Amplification on Solid SurfacesLadaTech Sues Illumina Over DNA Amplification PatentIllumina Files ‘841 Patent Infringement Suit Against AffymetrixAffymetrix and Illumina Settle Case Over ‘243, ‘432, ‘531, ‘365, and ‘716Applied Biosystems and Illumina Claims and Counter-claims Over Sequencing-by-Ligation BothUnsuccessfulFluidigm and Applied Biosystems Agree to End CaseBeckman Coulter and Applied Biosystems Settle Outstanding Legal DisputesCepheid and Idaho Technology Settle Dispute Over PCR PatentsEnzo Biochem Disputes CalTech Sequencing PatentsHuang v. CalTechApplied Biosystems and Amersham plc (GE Healthcare) Settle Sequencing Patent LitigationEarly ABI (Life Technologies) PatentsCHAPTER SEVEN: DEALSList of Deals in the Sequencing IndustryCHAPTER EIGHT: CORPORATE PROFILES454 Life Sciences (Roche)Complete GenomicsIlluminaLife TechnologiesPacific BiosciencesCHAPTER NINE: CHALLENGES AND STRATEGIC RECOMMENDATIONSMarket ChallengesFragmentation of Market Complicates Competitionand several others....Strategic RecommendationsIntense Competition Requires Constant Innovationand several others...List Of ExibitsCHAPTER ONE: EXECUTIVE SUMMARYFigure 1-1: DNA Sequencer Revenues, 2001-2011CHAPTER TWO: SEQUENCER MARKET TRENDS
  6. 6. Table 2-1: NHGRI Budget by Year Including ARRA Supplement, 2006-2012Figure 2-1: NHGRI Budget including ARRA (2006-2012)Table 2-2: Est. NHGRI Budget by Mechanism, 2012 ($M)Figure 2-2: NHGRI BudgetTable 2-3: NHGRI Budget by Activity, 2010-2012 ($thou)Figure 2-3: NHGRI Budget by Activity, 2012Table 2-4: NHGRI Funding, Large-Scale Sequencing Centers ‘07&’12Figure 2-4: NHGRI Funding, Large-Scale Sequencing Centers ‘07&’12Table 2-5: NHGRI Funding, Centers for Mendelian Genomics, 2012Figure 2-5: NHGRI Funding, Centers for Mendelian Genomics, 2012Table 2-6: NHGRI Clinical Sequencing Exploratory Research Awards, 2012Table 2-7: Fuge Funding RecipientsTable 2-8: Plant Genome Comparative Sequencing Program (PGCSP) Awards, FY 2011Table 2-9: NSF / USDA Microbial Genome Sequencing Program Awards, 2008-2011Table 2-10 Other Initiatives and Consortia Using DNA Sequencing, 2012CHAPTER THREE: DNA SEQUENCING SYSTEMS AND TECHNOLOGIESTable 3-1: DNA Sequencer Products/ Technologies, 2012Table 3-2: NIH Human Microbiome Project Technology Dev’t Awards, 2010Table 3-3: NHGRI $1,000 Genome Grant Awards, 2009Table 3-4: NHGRI $1,000 Genome Grant Awards, 2010Table 3-5: NHGRI $1,000 Genome Grant Awards, 2011Table 3-6: NHGRI Advanced Sequencing Technology Awardees, 2009Table 3-7: NHGRI Medical Sequencing Discovery Awards, 2009Table 3-8: NHGRI Understanding Genome Function Awards, 2009Table 3-9: NHGRI Population Genomics Awards, 2009Table 3-10: NHGRI Advanced Sequencing Technology Awardees, 2009Table 3-11: Other Initiatives and Consortia Supporting Technology Development, 2012CHAPTER FOUR: SEQUENCING MARKET ANALYSISFigure 4-1: Cost of Sequencing a GenomeTable 4-1: Market Forecast by Segment (Systems, Consumables, Services) , 2011-2016Table 4-2: Sequencing Market Revenues Growth Rates by Segment, 2011-2016 (Systems,Consumables, Services)Table 4-3: Sequencer Equipment Market, 2001-2011 ($M)Table 4-4: Growth Rates, Sequencer Equipment Market, 2001-2011 ($M)Figure 4-3: Sequencer Equipment Market, 2001-2011 ($M)Figure 4-4: ABI Sequencing Revenues, Q3 2001 – Q3 2008Figure 4-5: ABI Sequencing Revenues, Focus on Q4 2004 – Q3 2008Figure 4-6: DNA Sequencer Market Forecast, 2011-2016:Figure 4-7: Breakout of DNA Sequencing Market by Application(Clinical vs. Research) 2011Figure 4-8: Breakout of DNA Sequencing Market by Application(Clinical vs. Research) 2016CHAPTER FIVE: COMPETITIVE ANALYSISTable 5-1: DNA Sequencer Market Shares
  7. 7. Figure 5-1: DNA Sequencer Market SharesFigure 5-2: Pacific Biosciences Quarterly Revenues, 2011-2012 ($M)Figure 5-3: Complete Genomics Quarterly Revenues, 2010-2012 ($M)Table 5-2 Comparison of Sequencers’ Performance, mid-2012CHAPTER SIX: INTELLECTUAL PROPERTY AND LITIGATIONTable 6-1: PatentsCHAPTER SEVEN: DEALSTable 7-1: Deals in the Sequencer MarketContact: sales@reportsandreports.com for more information.